Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
The Oscillation for ARDS Treated Early (OSCILLATE) Trial
Status: Enrolling
Updated:  8/5/2015
Texas A&M HSC College of Medicine, Scott & White Hospital
mi
from
Temple, TX
The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
The Oscillation for ARDS Treated Early (OSCILLATE) Trial
Status: Enrolling
Updated: 8/5/2015
Texas A&M HSC College of Medicine, Scott & White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
The Oscillation for ARDS Treated Early (OSCILLATE) Trial
Status: Enrolling
Updated:  8/5/2015
Peter Lougheed Centre/Foothills Medical Centre
mi
from
Calgary,
The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
The Oscillation for ARDS Treated Early (OSCILLATE) Trial
Status: Enrolling
Updated: 8/5/2015
Peter Lougheed Centre/Foothills Medical Centre
mi
from
Calgary,
Click here to add this to my saved trials
Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters
Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters.
Status: Enrolling
Updated:  8/5/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters
Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters.
Status: Enrolling
Updated: 8/5/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated:  8/5/2015
University of South Alabama Medical Center
mi
from
Mobile, AL
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated: 8/5/2015
University of South Alabama Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated:  8/5/2015
University of California, San Diego, Thornton Hospital
mi
from
La Jolla, CA
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated: 8/5/2015
University of California, San Diego, Thornton Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated:  8/5/2015
BJJS, Corp., Memorial Hermann Memorial Medical Center
mi
from
Houston, TX
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated: 8/5/2015
BJJS, Corp., Memorial Hermann Memorial Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated:  8/5/2015
University of Virginia
mi
from
Charlottesville, VA
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics
Status: Enrolling
Updated: 8/5/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans
Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Institute University of California Irvine
mi
from
Irvine, CA
Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans
Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Institute University of California Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Institute University of California Irvine
mi
from
Irvine, CA
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Institute University of California Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Status: Enrolling
Updated:  8/5/2015
Trauma/Critical Care Units, UCI Medical Center
mi
from
Orange, CA
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Status: Enrolling
Updated: 8/5/2015
Trauma/Critical Care Units, UCI Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Landmark vs. Ultrasound Guided SCVC in the ED
Landmark vs. Ultrasound Guided Subclavian Central Venous Catheter Placement in the Emergency Department
Status: Enrolling
Updated:  8/7/2015
Maimonides Medical Center
mi
from
Brooklyn, NY
Landmark vs. Ultrasound Guided SCVC in the ED
Landmark vs. Ultrasound Guided Subclavian Central Venous Catheter Placement in the Emergency Department
Status: Enrolling
Updated: 8/7/2015
Maimonides Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery
Status: Enrolling
Updated:  8/7/2015
Shoals Medical Trials, Inc
mi
from
Sheffield, AL
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery
Status: Enrolling
Updated: 8/7/2015
Shoals Medical Trials, Inc
mi
from
Sheffield, AL
Click here to add this to my saved trials
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery
Status: Enrolling
Updated:  8/7/2015
Victory Medical Center
mi
from
Houston, CA
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery
Status: Enrolling
Updated: 8/7/2015
Victory Medical Center
mi
from
Houston, CA
Click here to add this to my saved trials
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery
Status: Enrolling
Updated:  8/7/2015
Research Concepts, LLC
mi
from
Houston, TX
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery
Status: Enrolling
Updated: 8/7/2015
Research Concepts, LLC
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury
Status: Enrolling
Updated:  8/10/2015
Baylor College of Medicine
mi
from
Houston, TX
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury
Status: Enrolling
Updated: 8/10/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated:  8/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated: 8/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated:  8/10/2015
Baystate Medical Center / WNERTA
mi
from
Springfield, MA
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated: 8/10/2015
Baystate Medical Center / WNERTA
mi
from
Springfield, MA
Click here to add this to my saved trials
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated:  8/10/2015
Montefiore Medical Center
mi
from
Bronx, NY
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated: 8/10/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated:  8/10/2015
Methodist Hospital
mi
from
Houston, TX
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated: 8/10/2015
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Alabama - Children's of Alabama - Clinical Virology
mi
from
Birmingham, AL
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Alabama - Children's of Alabama - Clinical Virology
mi
from
Birmingham, AL
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of South Alabama - Children's Specialty Clinic
mi
from
Mobile, AL
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of South Alabama - Children's Specialty Clinic
mi
from
Mobile, AL
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Arkansas Children's Hospital - Infectious Diseases
mi
from
Little Rock, AR
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Arkansas Children's Hospital - Infectious Diseases
mi
from
Little Rock, AR
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Los Angeles County - University of Southern California - Medical Center - Pediatrics
mi
from
Los Angeles, CA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Los Angeles County - University of Southern California - Medical Center - Pediatrics
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Plaza Towers Obstetrics and Gynecology
mi
from
Los Angeles, CA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Plaza Towers Obstetrics and Gynecology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Children's Hospital of Orange County - Infectious Diseases
mi
from
Orange, CA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Children's Hospital of Orange County - Infectious Diseases
mi
from
Orange, CA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Children's Hospital Colorado Infectious Disease
mi
from
Aurora, CO
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Children's Hospital Colorado Infectious Disease
mi
from
Aurora, CO
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease
mi
from
Washington,
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease
mi
from
Washington,
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Florida College of Medicine Jacksonville
mi
from
Jacksonville, FL
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Florida College of Medicine Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of South Florida - Tampa General Hospital - Pediatrics
mi
from
Tampa, FL
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of South Florida - Tampa General Hospital - Pediatrics
mi
from
Tampa, FL
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Emory Children's Center - Pediatric Infectious Diseases
mi
from
Atlanta, GA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Emory Children's Center - Pediatric Infectious Diseases
mi
from
Atlanta, GA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Louisville School of Medicine - Kosair Childrens Hospital - Infectious Diseases
mi
from
Louisville, KY
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Louisville School of Medicine - Kosair Childrens Hospital - Infectious Diseases
mi
from
Louisville, KY
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Tulane University - Tulane Medical Center - Pediatrics
mi
from
New Orleans, LA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Tulane University - Tulane Medical Center - Pediatrics
mi
from
New Orleans, LA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Louisiana State University Health Shreveport - Pediatrics
mi
from
Shreveport, LA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Louisiana State University Health Shreveport - Pediatrics
mi
from
Shreveport, LA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Johns Hopkins Children's Center - Pediatric Infectious Diseases
mi
from
Baltimore, MD
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Johns Hopkins Children's Center - Pediatric Infectious Diseases
mi
from
Baltimore, MD
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Children's Hospital Boston - Infectious Diseases
mi
from
Boston, MA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Children's Hospital Boston - Infectious Diseases
mi
from
Boston, MA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Minnesota - Pediatric Infectious Disease
mi
from
Minneapolis, MN
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Minnesota - Pediatric Infectious Disease
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Mississippi - Children's Infectious Diseases
mi
from
Jackson, MS
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Mississippi - Children's Infectious Diseases
mi
from
Jackson, MS
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Children's Mercy Hospital and Clinics - Infectious Diseases
mi
from
Kansas City, MO
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Children's Mercy Hospital and Clinics - Infectious Diseases
mi
from
Kansas City, MO
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Washington University School of Medicine in St. Louis - Center for Clinical Studies
mi
from
Saint Louis, MO
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Washington University School of Medicine in St. Louis - Center for Clinical Studies
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Creighton University Medical Center - Medicine - Infectious Diseases
mi
from
Omaha, NE
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Creighton University Medical Center - Medicine - Infectious Diseases
mi
from
Omaha, NE
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Childrens Hospital at Saint Peters University Hospital - Allergy, Immunology and Infectious Diseases
mi
from
New Brunswick, NJ
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Childrens Hospital at Saint Peters University Hospital - Allergy, Immunology and Infectious Diseases
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Robert Wood Johnson Medical School - Pediatrics
mi
from
New Brunswick, NJ
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Robert Wood Johnson Medical School - Pediatrics
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Women & Children's Hospital of Buffalo - Infectious Diseases
mi
from
Buffalo, NY
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Women & Children's Hospital of Buffalo - Infectious Diseases
mi
from
Buffalo, NY
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Cohen Children's Medical Center - Pediatric Infectious Diseases
mi
from
Manhasset, NY
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Cohen Children's Medical Center - Pediatric Infectious Diseases
mi
from
Manhasset, NY
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Rochester Medical Center - Golisano Children's Hospital - Infectious Diseases
mi
from
Rochester, NY
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Rochester Medical Center - Golisano Children's Hospital - Infectious Diseases
mi
from
Rochester, NY
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
SUNY Upstate Medical University Hospital - Pediatrics
mi
from
Syracuse, NY
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
SUNY Upstate Medical University Hospital - Pediatrics
mi
from
Syracuse, NY
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Carolinas Medical Center - Pediatrics - Infectious Diseases
mi
from
Charlotte, NC
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Carolinas Medical Center - Pediatrics - Infectious Diseases
mi
from
Charlotte, NC
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
MetroHealth Medical Center - Pediatric Infectious Disease
mi
from
Cleveland, OH
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
MetroHealth Medical Center - Pediatric Infectious Disease
mi
from
Cleveland, OH
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Cleveland Clinic Main Campus - Center for Pediatric Infectious Diseases
mi
from
Cleveland, OH
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Cleveland Clinic Main Campus - Center for Pediatric Infectious Diseases
mi
from
Cleveland, OH
Click here to add this to my saved trials